[go: up one dir, main page]

BR9909076A - Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b - Google Patents

Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b

Info

Publication number
BR9909076A
BR9909076A BR9909076-7A BR9909076A BR9909076A BR 9909076 A BR9909076 A BR 9909076A BR 9909076 A BR9909076 A BR 9909076A BR 9909076 A BR9909076 A BR 9909076A
Authority
BR
Brazil
Prior art keywords
virus
subgroup
rsv
attenuated
measles
Prior art date
Application number
BR9909076-7A
Other languages
Portuguese (pt)
Inventor
Stephen A Udem
Mohinderjit S Sidhu
Valerie B Randolph
Deborah A Buonagurio
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR9909076A publication Critical patent/BR9909076A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

''VìRUS ATENUADO DO SARAMPO, RECOMBINANTEMENTE GERADO, ISOLADO, VìRUS DO SARAMPO, VìRUS SINCICIAL RESPIRATóRIO HUMANO (RSV), SUBGRUPO B, ATENUADO, RECOMBINANTEMENTE GERADO, ISOLADO, O RSV, SUBGRUPO B, VACINA PROCESSO PARA IMUNIZAçãO DE UM INDIVìDUO PARA INDUZIR PROTEçãO CONTRA VìRUS DO SARAMPO, PROCESSO PARA IMUNIZAçãO DE UM INDIVìDUO PARA INDUZIR PROTEçãO CONTRA O RSV, SUBGRUPO B, COMPOSIçãO, PROCESSO PARA PRODUçãO DE VìRUS DO SARAMPO INFECCIOSO ATENUADO, PROCESSO PARA PRODUçãO DE RSV INFECCIOSO ATENUADO SUBGRUPO B'' São descritos vírus de subgrupo B sincicial respiratório e vírus do sarampo atenuados, recombinantemente gerados, isolados, possuindo mutações de atenuação definida. Vacinas são formuladas compreendendo tais vírus e um veículo fisiologicamente aceitável. As vacinas são utilizadas para imunizar um indivíduo a fim de induzir proteção contra vírus do sarampo ou vírus sincicial respiratório do subgrupo B.'' MASSIVE ATTENUATED VIRUS, RECOMBINANTLY GENERATED, ISOLATED, MUSCLE VIRUS, SYNCHIC RESPIRATORY VIRUS, (HUMAN RESPIRATORY), SUBGROUP B, ATTENTIONED, RECOMMENDEDLY GENERATED, ISOLATED, SUGGESTED, SUGGESTED, SUGGESTED AGAINST SARAMPOUS VIRUS, PROCESS FOR IMMUNIZATION OF AN INDIVIDUAL TO INDUCE PROTECTION AGAINST RSV, SUBGROUP B, COMPOSITION, PROCESS FOR THE PRODUCTION OF ATTENUED INFECTIOUS SARAMUS VIRUS, THE PROCESS FOR THE SUGGESTED INFECTION OF THE UNDERSTOVED INFECTION OF THE UNDERSTOVED 'INFECTION respiratory syncytial and measles virus attenuated, recombinantly generated, isolated, having defined attenuation mutations. Vaccines are formulated comprising such viruses and a physiologically acceptable carrier. Vaccines are used to immunize an individual in order to induce protection against measles virus or subgroup B respiratory syncytial virus.

BR9909076-7A 1998-03-26 1999-03-22 Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b BR9909076A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7946698P 1998-03-26 1998-03-26
PCT/US1999/006225 WO1999049017A2 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Publications (1)

Publication Number Publication Date
BR9909076A true BR9909076A (en) 2000-12-05

Family

ID=22150746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909076-7A BR9909076A (en) 1998-03-26 1999-03-22 Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b

Country Status (9)

Country Link
EP (1) EP1064358A2 (en)
JP (1) JP2002507408A (en)
KR (1) KR20010080863A (en)
CN (2) CN1600852A (en)
AU (1) AU767193B2 (en)
BR (1) BR9909076A (en)
CA (1) CA2323927A1 (en)
IL (1) IL138681A0 (en)
WO (1) WO1999049017A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE343589T1 (en) * 2000-06-23 2006-11-15 Wyeth Corp MODOFIED MORBILLIVIRUS V PROTEINS
ES2330309T3 (en) * 2002-06-20 2009-12-09 Institut Pasteur INFECTIOUS cDNA OF AN APPROVED VACCINE VIRUS strain of SARAMPION. USE FOR IMMUNOGENIC COMPOSITIONS.
AU2004226369A1 (en) * 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
WO2008065752A1 (en) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Immunotherapeutic agent containing dirna as active ingredient
AU2009311287C1 (en) 2008-11-05 2015-02-19 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
JP6453063B2 (en) * 2014-12-02 2019-01-16 国立大学法人北海道大学 Adjuvant composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045581B2 (en) * 1991-10-14 2000-05-29 社団法人北里研究所 Measles vaccine virus strain identification method
TW275632B (en) * 1992-04-21 1996-05-11 American Cyanamid Co
EP0932684A2 (en) * 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Also Published As

Publication number Publication date
WO1999049017A3 (en) 1999-12-16
EP1064358A2 (en) 2001-01-03
CN1177927C (en) 2004-12-01
KR20010080863A (en) 2001-08-25
CA2323927A1 (en) 1999-09-30
CN1294628A (en) 2001-05-09
CN1600852A (en) 2005-03-30
AU767193B2 (en) 2003-11-06
WO1999049017A2 (en) 1999-09-30
JP2002507408A (en) 2002-03-12
IL138681A0 (en) 2001-10-31
AU3109599A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
BR9812232A (en) Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic
BRPI9710363B1 (en) attenuated recombinant respiratory syncytial virus (rsv) particle, vaccine to induce protection against recombinant respiratory syncytial virus (rsv), expression vector, and method of producing an infectious recombinant respiratory syncytial virus (rsv).
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
ATE196737T1 (en) ADJUVANTS FOR VACCINES AGAINST RESPIRATORY SYNCITIAL VIRUS
IL153474A0 (en) Human papilloma virus treatment
ATE250937T1 (en) VACCINE PREPARATIONS CONTAINING CHITOSAN AND INFLUENZA ANTIGEN(S) FOR ADMINISTRATION THROUGH A MUCOSA
PL398576A1 (en) Vaccine preparations, pharmaceutical preparations, attenuated influenza virus, vaccination methods, methods for the prevention of an infectious disease, methods of treatment or prevention of cancers, vaccine compositions and pharmaceutical compositions
NO20073151L (en) Methods and compositions for treating hepatitis C virus
TW226333B (en)
BR9712970A (en) Method for producing vaccine for protection against respiratory syncytial virus, mixture of purified fusion protein, immunogenic composition
EP2066332A4 (en) INFLUENZA VACCINE COMPRISING A MIXTURE OF MANNANE AND ANTIGEN OF INFLUENZA
MXPA01006214A (en) Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation.
ES2130189T3 (en) MUTANT RESPIRATORY SINCITIAL VIRUS (RSV) VACCINES CONTAINING SUCH VIRUSES AND USE PROCEDURES.
BR9909076A (en) Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b
WO2002009749A3 (en) Respiratory syncytial virus vaccine
HUP9700975A2 (en) Live attenuated rtx-producing bacteria of the family pasteurellaceae
NO890565L (en) PREVENTION AND TREATMENT OF RETROVIRAL DISEASE.
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
WO1996030045A1 (en) Vaccine for the immunoprophylaxis of the infection from feline immunodeficiency virus in the domestic cat
Thomson et al. Foot and Mouth Disease in Southern Africa: Re-evaluation of the approach to control
RU98105627A (en) VACCINES
RU97107302A (en) METHOD OF IMMUNIZATION AGAINST INFECTION Caused by Tick-borne Encephalitis Virus
EP0178928A3 (en) Vaccines

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A,9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1990 DE 25/02/2009.